Monomethyl Fumarate (Bafiertam): A Comprehensive Pharmacological and Clinical Review

1.0 Executive Summary & Overview

Monomethyl Fumarate (MMF), commercially available as Bafiertam®, is an orally administered disease-modifying therapy (DMT) approved by the United States Food and Drug Administration (FDA) for the treatment of relapsing forms of multiple sclerosis (MS) in adult patients.[1] This small molecule represents a significant and logical evolution within the fumarate class of therapeutics. It is the direct, pharmacologically active metabolite of the widely prescribed prodrugs dimethyl fumarate (DMF), marketed as Tecfidera®, and diroximel fumarate (DRF), marketed as Vumerity®.[3] The development of this direct-delivery formulation was predicated on achieving bioequivalence with its parent prodrugs while aiming to provide an improved gastrointestinal (GI) tolerability profile, which has been a notable clinical challenge limiting the use of earlier fumarate therapies in some patients.[7]

The therapeutic effects of MMF are understood to be multifactorial, with the primary mechanism of action being the activation of the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) transcriptional pathway.[5] This pathway serves as a master regulator of the cellular response to oxidative stress, a fundamental pathological driver in the neuroinflammatory and neurodegenerative cascade of multiple sclerosis.[12] Beyond its potent antioxidant effects, MMF exerts broad immunomodulatory properties, including the capacity to shift the systemic immune response toward a more anti-inflammatory state and inhibit the migration of pathogenic immune cells across the blood-brain barrier into the central nervous system (CNS).[12]

The clinical efficacy of MMF is firmly established through a pharmacokinetic bridging approach to its prodrug, DMF. This regulatory strategy allows Bafiertam® to leverage the extensive and robust data from the pivotal Phase III clinical trials, DEFINE and CONFIRM.[16] These landmark studies demonstrated that treatment with the fumarate active moiety results in statistically significant and clinically meaningful reductions in the annualized relapse rate (ARR), a delay in the progression of physical disability, and a marked decrease in inflammatory lesion activity on magnetic resonance imaging (MRI) when compared to placebo.[19] The safety profile of MMF is consequently well-characterized, with the most frequently reported adverse events being flushing and various GI disturbances.[1] However, treatment necessitates diligent clinical and laboratory monitoring for serious risks, including the potential for significant lymphopenia, drug-induced liver injury, and the rare but severe opportunistic brain infection known as progressive multifocal leukoencephalopathy (PML).[1]

In the clinical landscape of MS treatment, Bafiertam® provides healthcare professionals and patients with a therapeutic option that combines the established, long-term efficacy of the fumarate class with a formulation designed to potentially mitigate some of the initial tolerability challenges. This may, in turn, enhance patient adherence and contribute to improved long-term disease management outcomes.

2.0 Identification and Physicochemical Profile

A comprehensive understanding of a pharmaceutical agent begins with its precise identification and a detailed characterization of its physical and chemical properties. These foundational data are critical for manufacturing, formulation, regulatory affairs, and preclinical research.

2.1 Nomenclature and Chemical Identity

Monomethyl fumarate is a well-defined small molecule with a consistent nomenclature and set of identifiers across major chemical and pharmacological databases.

• Generic Name: Monomethyl fumarate.[24]
• Brand Name: The sole brand name under which monomethyl fumarate is marketed for clinical use is Bafiertam®.[1]
• Drug Type: It is classified as a Small Molecule drug.[24] Therapeutically, it is categorized as an Nrf2 activator and an immunomodulator, reflecting its primary mechanisms of action in multiple sclerosis.[25]
• Systematic (IUPAC) Name: The formal chemical name according to the International Union of Pure and Applied Chemistry (IUPAC) is (E)-4-methoxy-4-oxobut-2-enoic acid.[4] The "(E)" prefix, derived from the German entgegen (opposite), specifies the trans configuration of the substituents across the carbon-carbon double bond, which is characteristic of fumaric acid derivatives.
• Synonyms: The compound is known by several synonyms in scientific literature and chemical catalogs, including: Fumaric acid monomethyl ester, Methyl hydrogen fumarate, MMF, (2E)-4-Methoxy-4-oxobut-2-enoic acid, methylhydrogenfumarate, and mono-Methyl fumarate.[3]
• Standard Identifiers: To ensure unambiguous identification, MMF is assigned unique codes in various international databases:
• DrugBank ID: DB14219 [4]
• CAS Number: 2756-87-8 [4]
• FDA UNII: 45IUB1PX8R [27]
• ChEBI ID: CHEBI:167450 [27]
• KEGG DRUG ID: D11492 [27]
• PubChem CID: 5369209 [4]

2.2 Structural and Chemical Properties

The structural and physicochemical characteristics of MMF define its behavior in biological systems, including its absorption, distribution, and ability to interact with molecular targets.

• Chemical Formula: The empirical formula for monomethyl fumarate is C5​H6​O4​.[3]
• Molecular Weight: The average molecular weight is calculated as 130.10 g/mol. The precise monoisotopic mass is 130.026608673 g/mol, a value critical for high-resolution mass spectrometry analysis.[3]
• Chemical Structure Identifiers: The molecule's two-dimensional structure can be represented textually using standard chemical line notations:
• SMILES: COC(=O)/C=C/C(=O)O [4]
• InChI: InChI=1S/C5H6O4/c1-9-5(8)3-2-4(6)7/h2-3H,1H3,(H,6,7)/b3-2+ [3]
• InChIKey: NKHAVTQWNUWKEO-NSCUHMNNSA-N [3]
• Physicochemical Characteristics:
• Physical State: At room temperature, MMF is a solid, typically appearing as an off-white or white to almost white powder or crystalline substance.[3]
• Melting Point: The reported melting point range is consistently between 144 °C and 149.0 °C.[31]
• Solubility: It exhibits limited solubility in common organic solvents, being described as slightly soluble in chloroform, dimethyl sulfoxide (DMSO), and methanol.[31] Quantitative data indicate solubilities of 10 mg/mL in dimethylformamide (DMF) and DMSO.[3]
• Acidity (pKa): The predicted acid dissociation constant (pKa) for the carboxylic acid group is approximately 3.40, indicating it is a weak acid.[31]
• Maximum UV Absorption (λmax​): The molecule shows a maximum ultraviolet absorbance at a wavelength of 209 nm when dissolved in methanol.[31]

The classification of MMF as a "small molecule" is not merely a technical descriptor but is fundamental to its clinical utility.[24] This characteristic dictates several key therapeutic advantages. First, unlike large-molecule biologics such as monoclonal antibodies, small molecules are generally amenable to oral administration, a significant benefit for patient convenience and long-term adherence in a chronic condition like MS. Second, their low molecular weight and physicochemical properties allow them to readily cross cellular membranes to engage with intracellular targets. This is an absolute prerequisite for MMF's mechanism of action, which involves direct interaction with the Keap1-Nrf2 protein complex located within the cell's cytoplasm. Finally, the simple and well-defined chemical structure of a small molecule facilitates highly controlled and reproducible manufacturing processes, ensuring consistent purity and quality, as reflected in the uniform physicochemical data reported across multiple independent sources.[3] Therefore, its identity as a small molecule is the essential feature that enables MMF to function as an orally bioavailable therapy targeting a critical intracellular signaling pathway.

Property	Value / Description	Source(s)
Generic Name	Monomethyl fumarate	24
Brand Name	Bafiertam	1
IUPAC Name	(E)-4-methoxy-4-oxobut-2-enoic acid	4
CAS Number	2756-87-8	30
DrugBank ID	DB14219	4
Chemical Formula	C5​H6​O4​	24
Molecular Weight	130.10 g/mol (Average)	3
Physical State	Off-white to white solid powder/crystal	3
Melting Point	144–149 °C	31
Solubility	Slightly soluble in DMSO, Methanol	31
pKa	3.40 ± 0.10 (Predicted)	31
SMILES	COC(=O)/C=C/C(=O)O	27

3.0 Preclinical and Clinical Pharmacology

The therapeutic efficacy of monomethyl fumarate in multiple sclerosis stems from a multifaceted mechanism of action that combines potent antioxidant, immunomodulatory, and neuroprotective effects. While the precise interplay of these activities is still under investigation, the activation of the Nrf2 pathway is recognized as its central pharmacological principle.

3.1 Primary Mechanism of Action: Nrf2 Pathway Activation

The principal therapeutic mechanism of MMF is the robust activation of the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) transcriptional pathway.[5] This pathway is a master regulator of cellular defense against oxidative stress, a well-established contributor to the neuroinflammatory and neurodegenerative pathology that characterizes multiple sclerosis.[11]

Under normal physiological conditions, the Nrf2 protein is held inactive in the cytoplasm through its binding to an inhibitor protein, Kelch-like ECH-associated protein 1 (Keap1). Keap1 acts as an adaptor, facilitating the continuous ubiquitination and subsequent degradation of Nrf2 by the proteasome, thereby keeping its activity low.[10] MMF, being an electrophilic α,β-unsaturated carboxylic acid ester, disrupts this homeostatic control. It covalently modifies highly reactive cysteine residues on the Keap1 protein (notably Cys151, Cys273, and Cys288) through a Michael addition reaction.[10] This chemical modification induces a conformational change in Keap1, impairing its ability to target Nrf2 for degradation.[10]

As a result, newly synthesized Nrf2 is stabilized, leading to its accumulation in the cytoplasm and subsequent translocation into the cell nucleus.[10] Once in the nucleus, Nrf2 heterodimerizes with other transcription factors and binds to a specific DNA sequence known as the Antioxidant Response Element (ARE), which is located in the promoter region of a large array of target genes.[10] This binding event initiates the coordinated transcription and upregulation of numerous cytoprotective and antioxidant enzymes. These include heme oxygenase-1 (HO-1), NAD(P)H dehydrogenase [quinone] 1 (NQO1), and various enzymes critical for the synthesis and recycling of the cell's primary antioxidant, glutathione (GSH).[3] The resulting enhancement of the cell's antioxidant capacity enables it to more effectively neutralize harmful reactive oxygen species (ROS), thereby reducing oxidative stress, dampening inflammation, and protecting CNS cells from damage.[5] The critical role of this pathway is underscored by preclinical studies in Nrf2 knockout mice, where the beneficial effects of MMF on upregulating antioxidant genes and suppressing inflammatory gene expression were completely abrogated, confirming that its primary action is Nrf2-dependent.[37]

3.2 Broader Immunomodulatory Effects

While Nrf2 activation is central, the therapeutic profile of MMF is pleiotropic, extending to broader immunomodulatory actions that are highly relevant to the autoimmune nature of MS. It actively reshapes the immune response, moving it from a pro-inflammatory to a more regulated, anti-inflammatory state.

A key aspect of this immunomodulation is the inhibition of the pro-inflammatory Nuclear Factor-kappa B (NF-κB) pathway.[5] The Nrf2 and NF-κB signaling pathways are known to have a reciprocal inhibitory relationship. By potently activating Nrf2, MMF indirectly suppresses NF-κB activity, which in turn leads to a decreased production of a wide range of pro-inflammatory cytokines and mediators.[12] This dual action—simultaneously boosting endogenous antioxidant defenses while actively suppressing key inflammatory signaling cascades—is a cornerstone of its therapeutic effect in MS.

MMF also exerts direct effects on various immune cell populations that are pivotal in MS pathogenesis:

• Dendritic Cells (DCs): MMF has been shown to impair the maturation and activation of DCs. This is a crucial intervention, as DCs are the primary antigen-presenting cells that initiate the autoimmune response by activating pathogenic T cells. MMF-treated DCs exhibit a reduced capacity to stimulate T cells and produce lower levels of key pro-inflammatory cytokines such as interleukin-12 (IL-12) and tumor necrosis factor-alpha (TNF-α).[5]
• T Lymphocytes: MMF directly modulates T-cell differentiation and function. It promotes a decisive shift in the T-helper cell balance, away from the pro-inflammatory Th1 and Th17 phenotypes that drive myelin damage, and toward a more anti-inflammatory Th2 phenotype.[6] This results in reduced secretion of pathogenic cytokines like interferon-gamma (IFN-γ) and IL-17.[41]
• Monocytes: MMF reduces CNS inflammation by limiting the trafficking of immune cells across the blood-brain barrier (BBB). It achieves this by decreasing the expression of vascular cell adhesion molecules on endothelial cells, which are necessary for the adhesion and subsequent migration of monocytes into the brain and spinal cord.[5]
• Natural Killer (NK) Cells: Preclinical evidence suggests that MMF can enhance the cytotoxic activity of NK cells, particularly their ability to lyse immature DCs. This action could further disrupt the antigen presentation process that fuels the proliferation of autoreactive T cells.[3]

Furthermore, MMF has been identified as an agonist of the hydroxycarboxylic acid 2 (HCA2) receptor, also known as GPR109A.[3] The activation of this G-protein coupled receptor, which is expressed on various immune cells including neutrophils and macrophages, contributes to the anti-inflammatory effects of MMF, such as the observed reduction in neutrophil adhesion and migration.[3]

3.3 Neuroprotective Mechanisms

Beyond its immunomodulatory effects, MMF is believed to confer direct neuroprotection within the CNS, helping to preserve neuronal integrity in the face of inflammatory and oxidative insults.

The activation of the Nrf2 pathway provides direct cytoprotection to CNS-resident cells. This has been demonstrated in vitro in human astrocytes and in preclinical animal models of ischemia-reperfusion injury, where MMF treatment mitigated neuronal cell loss.[5] The Nrf2 pathway is also intrinsically linked to mitochondrial health and biogenesis. By mitigating ROS-related damage and positively regulating the expression of Nuclear Respiratory Factor 1 (NRF1), MMF may help support the function of mitochondria, which are highly vulnerable to damage and dysfunction in the MS brain.[35] Although requiring further investigation, some research also points toward a potential role for MMF in promoting the survival and function of oligodendrocytes, the myelin-producing cells of the CNS, which could theoretically aid in myelin repair processes.[11]

A critical nuance in understanding the pharmacology of fumarates is the potential for distinct effects between the prodrug DMF and its active metabolite MMF. While Bafiertam's approval is based on achieving bioequivalent MMF exposure to Tecfidera, some preclinical evidence introduces a layer of complexity. For instance, one in vivo study suggested that DMF and MMF induce some non-overlapping pharmacodynamic responses and that DMF itself produced a more robust clinical effect in a mouse model of MS.[43] Other research has pointed to differences in how the two molecules modify the cysteine residues on Keap1.[33] This raises the possibility that the parent prodrug, DMF, may exert some unique, transient biological effects before it is fully hydrolyzed to MMF. While the clinical significance of this is unknown, it suggests that MMF cannot be viewed as a simple, one-to-one replacement for DMF in all mechanistic aspects. This distinction underscores that while Bafiertam's direct delivery of MMF is designed to improve GI tolerability, the complete therapeutic profile might have subtle differences from that of its parent prodrug, representing an important area for future research.

Ultimately, the mechanism of MMF is better characterized as pro-homeostatic rather than purely immunosuppressive. Unlike some MS therapies that cause broad immune cell depletion or functional blockade, MMF works by upregulating the body's own endogenous defense systems (Nrf2) and rebalancing the immune system away from a chronic pro-inflammatory state (via NF-κB inhibition and T-cell modulation).[10] It modulates, rather than ablates, immune function. This sophisticated, pro-homeostatic approach likely contributes to its favorable long-term safety profile relative to more profoundly immunosuppressive agents and helps explain why, despite known risks like lymphopenia, it is considered a valuable and manageable oral therapy for long-term use.

4.0 Comprehensive Pharmacokinetic Profile (ADME)

The pharmacokinetic profile of a drug, encompassing its absorption, distribution, metabolism, and excretion (ADME), is essential for determining its dosing regimen, understanding its potential for drug interactions, and predicting its behavior in the body. The pharmacokinetics of monomethyl fumarate are well-characterized and possess several clinically advantageous features.

4.1 Role as the Active Metabolite

A central tenet of fumarate pharmacology is that MMF is the primary and sole active metabolite responsible for the therapeutic effects of the prodrugs dimethyl fumarate (DMF) and diroximel fumarate (DRF).[3] Following oral administration, both DMF and DRF undergo rapid and extensive pre-systemic hydrolysis by ubiquitous esterase enzymes present in the gastrointestinal tract, blood, and various tissues.[36] This conversion is so efficient that plasma concentrations of the parent prodrugs are typically negligible or non-quantifiable. Consequently, all pharmacokinetic analyses and therapeutic effects are attributed to and measured by the systemic exposure of MMF.[42]

4.2 Absorption and Bioavailability

• Formulation: Bafiertam is supplied as a delayed-release capsule. This formulation is designed to protect the active ingredient from the acidic environment of the stomach and facilitate its release and absorption in the small intestine.[46]
• Time to Peak Concentration (Tmax​): When administered under fasting conditions, the median time to reach maximum plasma concentration (Tmax​) for MMF is approximately 4.0 hours.[5] This is slightly longer than the 2–2.5 hour Tmax​ observed for MMF following administration of the prodrug DMF.[36]
• Effect of Food: The presence of food has a notable effect on the absorption rate but not the overall extent of absorption. Administration of Bafiertam with a high-fat, high-calorie meal does not significantly alter the total systemic exposure, as measured by the area under the concentration-time curve (AUC). However, it does decrease the peak plasma concentration (Cmax​) by approximately 20–40% and substantially delays the median Tmax​ from around 4 hours to approximately 11 hours.[5] This delay can be clinically useful for mitigating absorption-rate-dependent side effects like flushing.
• Bioequivalence: A pivotal aspect of Bafiertam's development was the demonstration of bioequivalence to Tecfidera. Clinical studies confirmed that a 190 mg dose of MMF (Bafiertam) provides equivalent systemic exposure (Cmax​ and AUC) of the active MMF moiety to that of a 240 mg dose of DMF (Tecfidera).[5] This bioequivalence finding was the cornerstone of Bafiertam's regulatory approval, as it allowed the new formulation to bridge to the extensive efficacy and safety data already established for Tecfidera.[17]

4.3 Distribution

• Volume of Distribution (Vd​): The apparent volume of distribution for MMF in healthy individuals ranges from 53 to 73 liters.[5] This value, which is larger than the volume of total body water, indicates that the drug is well-distributed into extravascular tissues beyond the bloodstream.
• Plasma Protein Binding: MMF is moderately bound to human plasma proteins, with the bound fraction ranging from 27% to 45%. This binding is not dependent on the plasma concentration of the drug.[5]

4.4 Metabolism

The metabolic profile of MMF is a key feature contributing to its safety and predictability.

• Metabolic Pathway: MMF is metabolized through the tricarboxylic acid (TCA) cycle, also known as the Krebs cycle. This is a fundamental and ubiquitous cellular pathway for energy production.[5]
• CYP450 System Independence: Crucially, the metabolism of MMF does not involve the cytochrome P450 (CYP450) enzyme system.[5]
• Metabolites: The major metabolites of MMF found in plasma are fumaric acid, citric acid, and glucose. These are all natural, endogenous substances integral to normal cellular metabolism.[5]

This "clean" metabolic profile confers a significant clinical advantage. The independence of MMF metabolism from the CYP450 enzyme system dramatically reduces the potential for pharmacokinetic drug-drug interactions. Many medications are substrates, inhibitors, or inducers of CYP enzymes, and co-administration can lead to unpredictable changes in drug levels. For MS patients, who often require multiple medications to manage symptoms and comorbidities, MMF's lack of reliance on this pathway simplifies prescribing and enhances safety. Furthermore, the fact that MMF is metabolized into common, endogenous cellular components means there is no accumulation of novel or potentially toxic metabolites to consider, contributing to a more predictable and generally safer long-term profile.

4.5 Excretion

• Primary Route: The predominant route of elimination for MMF is via exhalation of carbon dioxide (CO2​), which accounts for approximately 60% of the originally administered dose.[5] This reflects its entry into the TCA cycle.
• Minor Routes: Renal elimination (excretion in urine) and fecal elimination are minor pathways, accounting for approximately 16% and 1% of the dose, respectively.[5] Only trace amounts of unchanged MMF are detectable in the urine.[40]
• Half-life (t1/2​): MMF is characterized by a very short terminal plasma half-life, reported to be between 30 and 60 minutes.[5]
• Accumulation: Due to this rapid elimination, MMF does not accumulate in the plasma with repeated twice-daily dosing. Plasma levels are typically undetectable in most individuals 24 hours after the last dose.[5]

The combination of a short half-life and rapid elimination creates what can be described as an "easy-on, easy-off" therapeutic profile, which provides significant clinical flexibility. If a patient experiences an acute, intolerable adverse event, discontinuation of the drug leads to its rapid clearance from the systemic circulation, allowing for a swift resolution of the side effect. This characteristic is particularly valuable in the context of family planning, as the drug can be cleared from the body quickly if a patient decides to become pregnant.[50] It also simplifies clinical management in situations requiring temporary cessation of therapy, such as during a serious infection, as the immunomodulatory pressure is removed promptly.[48] This contrasts sharply with other MS therapies that have very long biological half-lives, where effects can persist for weeks or months after the last dose, complicating such clinical decisions.

Parameter	Value / Description	Source(s)
Tmax​ (fasting)	~4.0 hours	5
Tmax​ (fed)	~11 hours (delayed by high-fat meal)	5
Cmax​ (effect of food)	Decreased by ~20% with a high-fat meal	5
AUC (effect of food)	Not significantly affected	5
Volume of Distribution (Vd​)	53–73 L	5
Plasma Protein Binding	27–45%	5
Metabolism Pathway	Tricarboxylic Acid (TCA) Cycle; No CYP450 involvement	5
Primary Elimination Route	~60% as exhaled CO2​	5
Half-life (t1/2​)	~0.5–1 hour	5

5.0 Clinical Efficacy in Relapsing Multiple Sclerosis

The clinical utility of monomethyl fumarate is firmly established for the management of relapsing forms of multiple sclerosis. Its approval was based on a well-defined regulatory strategy that leveraged extensive data from pivotal clinical trials of its prodrug, dimethyl fumarate.

5.1 Approved Indications and Therapeutic Goals

• FDA-Approved Indications: Bafiertam (monomethyl fumarate) is specifically indicated by the U.S. FDA for the treatment of relapsing forms of multiple sclerosis in adult patients. This broad indication encompasses the full spectrum of relapsing MS, including:
• Clinically Isolated Syndrome (CIS): The first clinical episode suggestive of MS.
• Relapsing-Remitting MS (RRMS): The most common form of MS, characterized by distinct relapses followed by periods of recovery.
• Active Secondary Progressive MS (SPMS): A later stage of the disease characterized by progressive disability, but with ongoing relapse activity.

[1]

• Therapeutic Goals: As a disease-modifying therapy, the primary objectives of treatment with MMF are to alter the underlying course of the disease. This includes reducing the frequency and severity of clinical relapses (also known as attacks or exacerbations), delaying the accumulation of irreversible physical disability, and slowing the development of new inflammatory brain lesions as visualized on MRI.[7] It is important to note that while MMF is effective in controlling MS disease activity and progression, it is not a cure for the condition.[31]

5.2 Pivotal Trial Evidence (Bridged from DEFINE & CONFIRM Studies)

The clinical efficacy of Bafiertam was established not through new, large-scale Phase III trials, but through a pharmacokinetic bridging strategy. By demonstrating that Bafiertam achieves bioequivalent systemic exposure of the active MMF moiety compared to Tecfidera (dimethyl fumarate), the wealth of efficacy data from the two pivotal, two-year, randomized, placebo-controlled Phase III trials of DMF—known as DEFINE and CONFIRM—is directly applicable to Bafiertam.[17] This regulatory approach, utilizing the 505(b)(2) pathway, represents a strategic and efficient method for drug development. It accelerates patient access to a new formulation with potential tolerability benefits without the need to repeat extensive and costly efficacy studies, thereby leveraging the robust, existing evidence base for the active compound.

• DEFINE Trial (Determination of the Efficacy and safety of oral Fumarate IN relapsing-rEmitting MS): This trial enrolled over 1,200 patients with RRMS.
• Primary Endpoint (Proportion of Patients Relapsing): Treatment with DMF 240 mg twice daily (BID) resulted in a highly significant reduction in the proportion of patients who experienced a relapse over two years. Only 27% of patients in the DMF group relapsed, compared to 46% in the placebo group, which corresponds to a 49% relative risk reduction (p<0.0001).[19]
• Annualized Relapse Rate (ARR): DMF treatment led to a 53% relative reduction in the ARR compared to placebo (0.172 for DMF vs. 0.364 for placebo; p<0.0001).[19]
• CONFIRM Trial (Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis): This trial enrolled over 1,400 patients and included both a placebo and an active comparator (glatiramer acetate).
• Primary Endpoint (Annualized Relapse Rate): DMF 240 mg BID significantly reduced the ARR at two years by 44% relative to placebo (0.224 for DMF vs. 0.401 for placebo; p<0.0001).[20]
• Proportion of Patients Relapsing: The proportion of patients who relapsed was also significantly reduced, from 41% in the placebo group to 29% in the DMF group, representing a 34% relative risk reduction (p=0.0020).[20]

5.3 Impact on Disability Progression and MRI Outcomes

Beyond relapse reduction, the pivotal trials also assessed the impact of treatment on disability progression and MRI measures of disease activity, which are critical indicators of long-term outcomes in MS.

• Disability Progression: This was measured by the time to 12-week confirmed disability progression on the Expanded Disability Status Scale (EDSS).
• In the DEFINE trial, DMF 240 mg BID demonstrated a statistically significant and clinically meaningful effect, reducing the risk of disability progression by 38% compared to placebo. Progression was observed in 16% of DMF-treated patients versus 27% of placebo-treated patients (p=0.0050).[19]
• In the CONFIRM trial, the observed 21% risk reduction in disability progression did not reach statistical significance (p=0.25).[56] This discrepancy does not necessarily negate the drug's effect but rather highlights the inherent variability and statistical challenges in measuring disability progression over a two-year timeframe, especially when the overall rate of progression in the trial is low. An integrated analysis of both trials confirmed a significant overall effect on disability progression.[63] This underscores an important principle in clinical trial interpretation: a holistic view incorporating integrated analyses and long-term data provides a more accurate assessment than relying on a single secondary endpoint from one trial. The totality of evidence strongly supports a beneficial effect of fumarate therapy on slowing disability progression.
• MRI Lesion Activity: The effect of DMF on MRI markers of inflammation and tissue damage was profound and consistent across both pivotal trials.
• Gadolinium-enhancing (Gd+) Lesions: These lesions represent areas of active inflammation. Treatment with DMF led to relative reductions of 90% in DEFINE and 74% in CONFIRM compared to placebo.[18]
• New or Newly Enlarging T2-hyperintense Lesions: These lesions reflect the overall burden of disease and long-term impact. DMF treatment resulted in relative reductions of 85% in DEFINE and 71% in CONFIRM.[18]
• New T1-hypointense Lesions ("Black Holes"): These lesions are thought to represent areas of more severe tissue damage and axonal loss. DMF treatment reduced their development by 72% in DEFINE and 57% in CONFIRM.[20]

5.4 Long-Term Efficacy (ENDORSE Extension Study)

The ENDORSE study, a long-term, open-label extension of both DEFINE and CONFIRM, has provided crucial data on the sustained efficacy and safety of DMF treatment for up to 11 years.[64]

• Sustained Low Relapse Rates: Patients who were continuously treated with DMF from the start of the parent trials maintained a consistently low ARR (at or below 0.20) throughout the entire follow-up period. Importantly, patients who initially received placebo and then switched to DMF in ENDORSE experienced a substantial and sustained reduction in their relapse rate.[19]
• Long-Term Disability Stability: The vast majority of patients (approximately 73–74%) remained free of 24-week confirmed disability progression over 9 years of treatment. The mean EDSS scores for the cohort remained stable over this extended period, indicating a durable effect on preventing disability accumulation.[65]
• Sustained MRI Control: The potent effect on suppressing the formation of new inflammatory lesions was maintained over the long term. Furthermore, long-term data suggest that the rate of brain volume loss (atrophy), a key measure of neurodegeneration, was slowed in treated patients, approaching the rate observed in healthy individuals.[64]

Efficacy Endpoint	DEFINE Trial Results (DMF 240mg BID vs. Placebo)	CONFIRM Trial Results (DMF 240mg BID vs. Placebo)	Source(s)
Annualized Relapse Rate (ARR) - Relative Reduction	53% (p<0.0001)	44% (p<0.0001)	20
Proportion of Patients Relapsing - Relative Risk Reduction	49% (p<0.0001)	34% (p=0.0020)	20
12-Week Confirmed Disability Progression - Relative Risk Reduction	38% (p=0.0050)	21% (Not Significant)	20
New or Newly Enlarging T2 Lesions - Relative Reduction	85%	71%	18
Gd+ Lesions - Relative Reduction	90%	74%	18

6.0 Safety Profile, Tolerability, and Risk Management

The safety and tolerability profile of monomethyl fumarate is well-characterized, drawing from the extensive clinical trial program of its prodrug, dimethyl fumarate, postmarketing surveillance, and specific studies on the Bafiertam formulation. While generally considered to have a favorable benefit-risk profile, its use requires careful patient selection, counseling, and ongoing monitoring to mitigate potential adverse events.

6.1 Common and Manageable Adverse Events

The most frequently encountered side effects are related to flushing and gastrointestinal intolerance. These are typically most prominent upon treatment initiation and tend to diminish over time.

• Flushing: This is the most common adverse event associated with fumarate therapy, reported in up to 40% of patients in clinical trials.[1] It is characterized by a sensation of warmth, redness (erythema), itching (pruritus), and/or a burning sensation, primarily affecting the face, neck, and upper chest.[22] The reaction is generally mild to moderate in severity, occurs early in the treatment course, and often decreases in frequency and intensity with continued use.[23]
• Management: The incidence and severity of flushing can often be managed by administering the medication with food. Additionally, pre-treatment with a non-enteric-coated aspirin (up to a 325 mg dose) taken approximately 30 minutes prior to Bafiertam dosing has been shown to be effective in reducing flushing.[2]
• Gastrointestinal (GI) Events: A constellation of GI symptoms is also very common, particularly during the first month of therapy.[11] These include abdominal pain (reported in 18% of patients), diarrhea (14%), nausea (12%), and vomiting (9%).[22] Similar to flushing, these events are typically mild to moderate and transient.[11]
• Management: Patient counseling regarding the expected transient nature of these side effects is crucial for adherence. While taking the medication with food is a common recommendation, some patient literature suggests that taking it without food may alleviate certain GI symptoms, indicating that an individualized approach may be necessary.[23] The development of Bafiertam was driven by the hypothesis that direct delivery of MMF, bypassing the conversion of DMF in the gut, could improve GI tolerability. A head-to-head study in healthy volunteers supported this, demonstrating fewer and less severe GI events with Bafiertam compared to Tecfidera.[8] This suggests that while Bafiertam does not eliminate these side effects, it may offer a relative, incremental improvement in tolerability for some patients, which could be a critical factor in preventing early treatment discontinuation.

6.2 Serious Adverse Events and Warnings

While generally well-tolerated, MMF is associated with several rare but serious risks that mandate vigilant monitoring and risk management strategies.

• Progressive Multifocal Leukoencephalopathy (PML): This is a rare, opportunistic viral infection of the brain caused by the John Cunningham (JC) virus. It is a major safety concern as it typically occurs in immunocompromised individuals and usually leads to severe disability or death.[1]
• Risk Factor: The primary risk factor for developing PML in patients taking fumarates is the presence of prolonged, moderate to severe lymphopenia. Cases have occurred predominantly in patients with absolute lymphocyte counts (ALC) below 0.8×109/L that persist for more than six months.[2] A fatal case was documented in a clinical trial patient who had severe lymphopenia (ALC predominantly <0.5×109/L) for 3.5 years.[54] This clear association forms the cornerstone of the safety monitoring protocol.
• Monitoring and Management: Clinicians and patients must be vigilant for any new or worsening neurological symptoms, such as progressive weakness on one side of the body, clumsiness, vision disturbances, or changes in cognition, memory, or personality. MRI findings may be apparent before clinical symptoms emerge. Bafiertam must be withheld immediately at the first sign or symptom suggestive of PML, and an appropriate diagnostic evaluation must be performed.[2]
• Lymphopenia: MMF can cause a dose-dependent decrease in lymphocyte counts.[7] In clinical trials with DMF, mean lymphocyte counts decreased by approximately 30% during the first year of treatment and then remained stable.[50]
• Monitoring and Management: A complete blood count (CBC) with a differential and lymphocyte count is a mandatory baseline assessment before initiating therapy. This test must be repeated 6 months after starting treatment and then every 6 to 12 months thereafter, or more frequently as clinically indicated.[1] Interruption of therapy should be strongly considered if the ALC falls below 0.5×109/L and persists for more than six months.[2]
• Liver Injury: Clinically significant cases of drug-induced liver injury have been reported in the postmarketing setting with DMF.[1] The onset can range from a few days to several months after starting treatment. Signs of severe injury include elevations of serum aminotransferases to greater than 5 times the upper limit of normal (ULN) and elevations of total bilirubin to greater than 2 times the ULN.[55]
• Monitoring and Management: Liver function tests (LFTs), including serum aminotransferase (AST, ALT), alkaline phosphatase, and total bilirubin levels, must be obtained at baseline. LFTs should be monitored during treatment as clinically indicated, particularly if a patient develops symptoms suggestive of liver dysfunction (e.g., severe fatigue, anorexia, right upper quadrant pain, dark urine, or jaundice). Bafiertam should be discontinued if clinically significant drug-induced liver injury is suspected.[23]
• Anaphylaxis and Angioedema: Serious, life-threatening allergic reactions can occur. These can manifest after the first dose or at any time during treatment. Symptoms include difficulty breathing, urticaria (hives), and swelling of the throat and tongue.[1] This constitutes a medical emergency requiring immediate discontinuation of the drug and urgent medical care.[2]
• Herpes Zoster and Other Serious Opportunistic Infections: Serious cases of herpes zoster (shingles) have been reported, including disseminated forms and infections involving the CNS (e.g., meningoencephalitis).[1] Other serious opportunistic infections (viral, fungal, and bacterial) have also occurred. In patients who develop a serious infection, withholding Bafiertam treatment until the infection has resolved should be considered.[2]
• Serious Gastrointestinal Problems: Although GI side effects are typically mild to moderate, rare cases of serious GI events, including bleeding, ulcers, blockage, and perforation, have been reported with fumarate therapy.[1]

6.3 Contraindications, Precautions, and Drug Interactions

• Contraindications: Bafiertam is absolutely contraindicated in the following situations:
• Patients with a known hypersensitivity to monomethyl fumarate, dimethyl fumarate, diroximel fumarate, or any of the excipients in the formulation. Reactions can include anaphylaxis or angioedema.[2]
• Patients who are concurrently taking dimethyl fumarate (Tecfidera) or diroximel fumarate (Vumerity). Since all three drugs deliver the same active metabolite (MMF), co-administration would lead to an overdose and an increased risk of adverse reactions.[2]
• Precautions:
• Treatment should be initiated with caution in patients with pre-existing low lymphocyte counts or those with a serious active infection.[47]
• The safety of Bafiertam in pregnancy, during lactation, and in pediatric populations has not been established. It is classified as Pregnancy Category C. A pregnancy exposure registry has been established to collect and monitor outcomes in women exposed to the drug during pregnancy.[1]
• Drug Interactions:
• As MMF metabolism does not involve the CYP450 system, the risk of pharmacokinetic interactions with drugs metabolized by these enzymes is low.[5]
• The primary concern for drug interactions is pharmacodynamic, specifically the additive effects with other immunosuppressive or immunomodulating therapies. Co-administration with such agents can increase the risk of adverse effects, particularly infections and lymphopenia.[24]
• Major/Serious Interactions: Co-administration with other potent immunomodulators used in MS (e.g., natalizumab, fingolimod, ocrelizumab, alemtuzumab, cladribine), biologic agents used for other autoimmune conditions (e.g., abatacept, adalimumab), or certain antineoplastic agents (e.g., CAR-T therapies like axicabtagene ciloleucel) should be avoided or approached with extreme caution due to the significantly increased risk of infection and additive immunosuppressive effects.[24]
• Moderate Interactions: Caution is advised with the administration of live vaccines during treatment, as the patient's immune response may be blunted, potentially decreasing the efficacy of the vaccine and increasing the risk of developing an infection from the attenuated virus.[24]

Adverse Event Category	Specific Adverse Event	Incidence (from DMF trials)	Clinical Notes / Management	Source(s)
Very Common (>10%)	Flushing	40%	Mild-moderate, transient. Manage with food or pre-dose aspirin.	22
	Abdominal Pain	18%	Mild-moderate, transient. Manage with food.	22
	Diarrhea	14%	Mild-moderate, transient. Manage with food.	22
	Nausea	12%	Mild-moderate, transient. Manage with food.	22
Common (1-10%)	Pruritus (Itching)	8%	Often associated with flushing.	22
	Rash	8%	Typically mild.	22
	Vomiting	9%	Mild-moderate, transient.	22
	Dyspepsia	5%	Mild-moderate, transient.	22
	Lymphopenia	2%	Requires routine monitoring.	22
Serious (Frequency Variable)	Progressive Multifocal Leukoencephalopathy (PML)	Rare	Associated with prolonged lymphopenia. Withhold drug at first sign/symptom.	7
	Liver Injury	Rare	Monitor LFTs at baseline and as clinically indicated. Discontinue if suspected.	7
	Anaphylaxis / Angioedema	Rare	Can occur at any time. Medical emergency; discontinue immediately.	7
	Serious Infections (e.g., Herpes Zoster)	Rare	Withhold treatment until infection resolves.	7

Monitoring Parameter	Baseline (Pre-treatment)	Ongoing Monitoring Schedule	Action Thresholds / Clinical Considerations	Source(s)
CBC with Lymphocyte Count	Required	6 months after initiation, then every 6–12 months	Consider interruption if ALC < 0.5×109/L persists for >6 months. Monitor more frequently if ALC < 0.8×109/L.	26
Liver Function Tests (LFTs)	Required (AST, ALT, ALP, Total Bilirubin)	As clinically indicated (e.g., if symptoms of liver injury develop)	Discontinue if clinically significant drug-induced liver injury is suspected.	26
Clinical Assessment	N/A	At each patient visit	Monitor for new/worsening neurological symptoms (PML), signs of serious infection, or severe GI symptoms.	71

7.0 Dosage, Administration, and Regulatory Status

The effective and safe use of monomethyl fumarate requires adherence to specific guidelines regarding its formulation, dosing regimen, and administration. Its availability to patients is governed by regulatory approvals, which differ between major global regions.

7.1 Formulation and Dosing Regimen

• Available Formulation: Bafiertam is commercially available as a 95 mg soft gelatin delayed-release capsule.[26] The capsules are described as white, opaque, and oval, and are printed with "95" in black ink for identification.[54]
• Starting Dose: Treatment is initiated with a titration period to enhance tolerability. The recommended starting dose is one 95 mg capsule taken orally twice a day for the first 7 days.[2] This titration is not based on efficacy but is a critical strategy to allow the patient's body to acclimate to the drug, thereby reducing the incidence and severity of initial side effects like flushing and GI upset, which are the primary barriers to early treatment adherence.
• Maintenance Dose: Following the 7-day titration period, the dosage is increased to the full maintenance dose of 190 mg (administered as two 95 mg capsules) taken orally twice a day.[2]
• Dose Adjustment for Tolerability: The prescribing information includes a provision for managing patients who struggle with the side effects of the maintenance dose. A temporary dose reduction back to 95 mg twice a day may be considered. However, it is recommended that the patient attempt to resume the full 190 mg twice-daily maintenance dose within 4 weeks. For patients who are unable to tolerate the return to the maintenance dose, discontinuation of the therapy should be considered.[2] This built-in flexibility reinforces the importance of managing tolerability to ensure patients can remain on an effective therapeutic dose.

7.2 Administration Instructions

• Method of Administration: To ensure the integrity of the delayed-release mechanism, the capsules must be swallowed whole and intact. They should not be crushed, chewed, or opened to mix the contents with food.[2]
• Relation to Food: Bafiertam can be administered with or without food.[2] As noted previously, the presence of food can affect the rate of absorption and may be used strategically by patients and clinicians to manage side effects.
• Storage: Proper storage is essential to maintain the stability of the medication. Unopened bottles must be stored in a refrigerator at 2°C to 8°C (35°F to 46°F). Once a bottle is opened, it can be stored at controlled room temperature (20°C to 25°C or 68°F to 77°F) for up to 3 months. The capsules should be protected from light and must not be frozen.[25]

7.3 Regulatory Approvals and Development History

The regulatory landscape for fumarate therapies reveals a notable divergence between the United States and Europe, reflecting different regulatory philosophies and market strategies.

• U.S. Food and Drug Administration (FDA):
• Approval Pathway and Timeline: Bafiertam was developed and approved via the 505(b)(2) New Drug Application (NDA) pathway. This pathway allows an applicant to rely, in part, on the FDA's previous findings of safety and effectiveness for a previously approved drug (the "listed drug"), which in this case was Tecfidera (dimethyl fumarate).[82] Banner Life Sciences received a tentative approval from the FDA on November 16, 2018, which was contingent upon the resolution of a patent infringement lawsuit initiated by Biogen, the manufacturer of Tecfidera.[83] Following a court ruling in favor of Banner, the FDA granted final approval for Bafiertam on April 28, 2020.[5]
• Approved Indication: Bafiertam is approved for the treatment of relapsing forms of multiple sclerosis in adults.[82]
• European Medicines Agency (EMA):
• Status: Monomethyl fumarate, as Bafiertam, is not directly approved by the EMA. The approvals for fumarate-based therapies in the European Union have focused on the prodrugs.[87]
• Tecfidera (DMF): Received a marketing authorization valid throughout the EU on January 30, 2014, for the treatment of adults with RRMS.[89] This indication was later expanded to include adolescent patients from 13 years of age.[94]
• Vumerity (DRF): Received EMA marketing authorization on November 15-16, 2021, for the treatment of adults with RRMS. Its approval was also based on a bioequivalence approach, demonstrating similar MMF exposure to Tecfidera.[88]

This regulatory divergence has created a fragmented global market. A clinician in the United States has three oral fumarate options (Tecfidera, Vumerity, and Bafiertam), each with a slightly different profile regarding its formulation and tolerability data. In contrast, a clinician in the EU primarily has two options (Tecfidera and Vumerity). This difference impacts prescribing choices, market competition, and patient access to the specific formulation that may be best tolerated on an individual basis.

• Clinical Trials: While Bafiertam's approval was primarily based on bioequivalence studies demonstrating its pharmacokinetic similarity to Tecfidera [17], several other clinical trials have been conducted. A key study compared the GI tolerability of Bafiertam to Tecfidera in healthy volunteers.[99] A Phase 1 trial in patients with MS has been completed.[100] An observational study designed to assess treatment persistence in a real-world setting is also noted in clinical trial registries.[101]

8.0 Synthesis and Concluding Remarks

Monomethyl Fumarate, marketed as Bafiertam, represents a thoughtful and patient-centric refinement within the oral fumarate class of therapies for relapsing multiple sclerosis. Its fundamental identity as the direct, active metabolite of the well-established prodrug dimethyl fumarate allows it to inherit a wealth of robust, long-term efficacy and safety data. This provides a high degree of clinical confidence in its disease-modifying capabilities, which include significant reductions in relapse rates, a delay in disability progression, and potent suppression of MRI disease activity. The core therapeutic value of MMF is derived from its pleiotropic mechanism of action. This mechanism elegantly combines powerful Nrf2-mediated antioxidant and neuroprotective effects with broad immunomodulatory actions that serve to rebalance the immune system away from a pro-inflammatory state, rather than causing profound, non-specific immunosuppression.

The primary clinical innovation and differentiating feature of Bafiertam is the potential for an improved gastrointestinal tolerability profile when compared to its parent prodrug, Tecfidera. By delivering MMF directly to the systemic circulation and obviating the need for chemical conversion in the gut, it aims to mitigate one of the key factors that can lead to treatment discontinuation. While this benefit is nuanced and does not eliminate the risk of GI side effects, it provides a valuable alternative for patients who are particularly sensitive to the GI effects of DMF or may serve as a gentler starting option for fumarate-naïve individuals, potentially improving adherence during the critical initial phase of treatment.

From a pharmacological standpoint, the pharmacokinetic profile of MMF is highly favorable for a long-term therapy. Its metabolism through the endogenous TCA cycle, independent of the CYP450 system, minimizes the risk of drug-drug interactions, a crucial consideration for a patient population often requiring polypharmacy. Furthermore, its rapid elimination and short half-life create a flexible, "easy-on, easy-off" profile that simplifies the management of adverse events and accommodates life changes such as family planning. The central challenge in the clinical application of MMF remains the diligent management of its key safety risks. In particular, the potential for drug-induced lymphopenia and its established association with the rare but devastating risk of PML necessitates strict adherence to the established blood monitoring protocol.

In conclusion, Monomethyl Fumarate solidifies the role of the Nrf2 pathway as a key therapeutic target in multiple sclerosis. It offers clinicians and patients a valuable, effective, and potentially better-tolerated oral option in the ever-expanding armamentarium against this chronic and complex neurological disease.

Works cited

1. BAFIERTAM® (monomethyl fumarate) | Relapsing MS Treatment, accessed August 21, 2025, https://www.bafiertam.com/
2. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights ..., accessed August 21, 2025, https://www.bafiertam.com/pdf/bafiertam-prescribing-information.pdf
3. Monomethyl fumarate (CAS 2756-87-8) - Cayman Chemical, accessed August 21, 2025, https://www.caymanchem.com/product/27813/monomethyl-fumarate
4. Monomethyl fumarate - Wikipedia, accessed August 21, 2025, https://en.wikipedia.org/wiki/Monomethyl_fumarate
5. Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS) - PMC - PubMed Central, accessed August 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8162564/
6. Dimethyl fumarate - Wikipedia, accessed August 21, 2025, https://en.wikipedia.org/wiki/Dimethyl_fumarate
7. Why BAFIERTAM® for Multiple Sclerosis (MS), accessed August 21, 2025, https://www.bafiertam.com/why-bafiertam
8. Monomethyl fumarate has better gastrointestinal tolerability profile compared with dimethyl fumarate - PubMed, accessed August 21, 2025, https://pubmed.ncbi.nlm.nih.gov/32629403/
9. Bafiertam (monomethyl fumarate) - PHARMACY POLICY STATEMENT, accessed August 21, 2025, https://www.caresource.com/documents/medicaid-ga-policy-pharmacy-bafiertam-20230101.pdf
10. Recent advances in understanding NRF2 as a druggable target: development of pro-electrophilic and non-covalent NRF2 activators to overcome systemic side effects of electrophilic drugs like dimethyl fumarate. - F1000Research, accessed August 21, 2025, https://f1000research.com/articles/6-2138
11. What is Monomethyl fumarate used for? - Patsnap Synapse, accessed August 21, 2025, https://synapse.patsnap.com/article/what-is-monomethyl-fumarate-used-for
12. Utilization of Dimethyl Fumarate and Related Molecules ... - Frontiers, accessed August 21, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2016.00278/full
13. Monomethyl Fumarate - Inxight Drugs, accessed August 21, 2025, https://drugs.ncats.io/drug/45IUB1PX8R
14. Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of ... - MDPI, accessed August 21, 2025, https://www.mdpi.com/2035-8377/13/2/22
15. What is the mechanism of Monomethyl fumarate? - Patsnap Synapse, accessed August 21, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-monomethyl-fumarate
16. 211855Orig1s000 - accessdata.fda.gov, accessed August 21, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211855Orig1s000ClinPharmR.pdf
17. Monomethyl fumarate (Bafiertam) - Multiple Sclerosis Centers of Excellence - VA.gov, accessed August 21, 2025, https://www.va.gov/MS/TREATING_MS/DMTs/Monomethyl_fumarate_Bafiertam.asp
18. Bafiertam® | MSAA, accessed August 21, 2025, https://mymsaa.org/treatment/bafiertam/
19. Data show effects of TECFIDERA in newly-diagnosed and early disease course multiple sclerosis patients, accessed August 21, 2025, https://www.mscare.org/data-show-effects-of-tecfidera-in-newly-diagnosed-and-early-disease-course-multiple-sclerosis-patients/
20. TECFIDERA Effectiveness | Tecfidera® (dimethyl fumarate), accessed August 21, 2025, https://www.tecfidera.com/en_us/home/about/benefits.html
21. Dimethyl fumarate in the treatment of relapsing–remitting multiple ..., accessed August 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4286944/
22. Monomethyl Fumarate Side Effects: Common, Severe, Long Term, accessed August 21, 2025, https://www.drugs.com/sfx/monomethyl-fumarate-side-effects.html
23. BAFIERTAM Patient Fact Sheet, accessed August 21, 2025, https://bafiertam.com/pdf/bafiertam-patient-fact-sheet.pdf
24. Monomethyl fumarate: Uses, Interactions, Mechanism of Action ..., accessed August 21, 2025, https://go.drugbank.com/drugs/DB14219
25. Bafiertam (monomethyl fumarate): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD, accessed August 21, 2025, https://www.webmd.com/drugs/2/drug-179759/bafiertam-oral/details
26. Bafiertam (monomethyl fumarate) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed August 21, 2025, https://reference.medscape.com/drug/bafiertam-monomethyl-fumarate-4000037
27. Monomethyl Fumarate | C5H6O4 | CID 5369209 - PubChem, accessed August 21, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Monomethyl-Fumarate
28. 2756-87-8|(E)-4-methoxy-4-oxobut-2-enoic acid - BLDpharm, accessed August 21, 2025, https://www.bldpharm.com/products/2756-87-8.html
29. monomethyl fumarate (CHEBI:167450) - EMBL-EBI, accessed August 21, 2025, https://www.ebi.ac.uk/chebi/searchId.do;jsessionid=F46C766782153703E7A1476139029B4C?chebiId=CHEBI%3A167450
30. mono-Methyl fumarate | CAS 2756-87-8 | SCBT - Santa Cruz Biotechnology, accessed August 21, 2025, https://www.scbt.com/p/mono-methyl-fumarate-2756-87-8
31. Monomethyl fumarate | 2756-87-8 - ChemicalBook, accessed August 21, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7505423.htm
32. Monomethyl Fumarate 2756-87-8 | TCI AMERICA - TCI Chemicals, accessed August 21, 2025, https://www.tcichemicals.com/US/en/p/M2413
33. Dimethyl Fumarate and Monoethyl Fumarate Exhibit Differential ..., accessed August 21, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0120254
34. Dimethyl Fumarate Triggers the Antioxidant Defense System in Human Retinal Endothelial Cells through Nrf2 Activation - MDPI, accessed August 21, 2025, https://www.mdpi.com/2076-3921/11/10/1924
35. Dimethyl fumarate mediates Nrf2-dependent mitochondrial biogenesis in mice and humans - Oxford Academic, accessed August 21, 2025, https://academic.oup.com/hmg/article/26/15/2864/3778357
36. Novel potential pharmacological applications of dimethyl fumarate—an overview and update - Frontiers, accessed August 21, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1264842/full
37. Monomethyl fumarate promotes Nrf2-dependent neuroprotection in ..., accessed August 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4687295/
38. Effects of dimethyl fumarate on neuroprotection and immunomodulation - PubMed, accessed August 21, 2025, https://pubmed.ncbi.nlm.nih.gov/22769044/
39. Immunomodulatory effects of dimethyl fumarate (DMF), monomethyl... | Download Scientific Diagram - ResearchGate, accessed August 21, 2025, https://www.researchgate.net/figure/Immunomodulatory-effects-of-dimethyl-fumarate-DMF-monomethyl-fumarate-MMF-and_fig3_386486179
40. Dimethyl fumarate: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 21, 2025, https://go.drugbank.com/drugs/DB08908
41. Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2 | PNAS, accessed August 21, 2025, https://www.pnas.org/doi/10.1073/pnas.1603907113
42. Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™ (Monomethyl Fumarate) or Tecfidera® (Dimethyl Fumarate) | springermedizin.de, accessed August 21, 2025, https://www.springermedizin.de/pharmacokinetics-and-bioavailability-of-monomethyl-fumarate-foll/24116260
43. Dimethyl Fumarate and Monomethyl Fumarate are Distinguished by Non-Overlapping Pharmacodynamic Effects In Vivo (P1.206) - Neurology.org, accessed August 21, 2025, https://www.neurology.org/doi/10.1212/WNL.82.10_supplement.P1.206
44. New and Old Horizons for an Ancient Drug: Pharmacokinetics, Pharmacodynamics, and Clinical Perspectives of Dimethyl Fumarate - MDPI, accessed August 21, 2025, https://www.mdpi.com/1999-4923/14/12/2732
45. Pharmacokinetics and Bioavailability of Monomethyl Fumarate ..., accessed August 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8144082/
46. Monomethyl Fumarate: MedlinePlus Drug Information, accessed August 21, 2025, https://medlineplus.gov/druginfo/meds/a622028.html
47. Monomethyl fumarate (oral route) - Side effects & dosage - Mayo Clinic, accessed August 21, 2025, https://www.mayoclinic.org/drugs-supplements/monomethyl-fumarate-oral-route/description/drg-20489606
48. Monomethyl Fumarate (Bafiertam) | Davis's Drug Guide - Nursing Central, accessed August 21, 2025, https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110858/9/monomethyl_fumarate
49. APPLICATION NUMBER: - 210296Orig1s000 CLINICAL PHARMACOLOGY REVIEW(S) - accessdata.fda.gov, accessed August 21, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210296Orig1s000ClinPharmR.pdf
50. BAFIERTAM® HCP Brochure, accessed August 21, 2025, https://www.bafiertamhcp.com/pdf/hcp-leave-behind.pdf
51. Dimethyl Fumarate - PMC - PubMed Central, accessed August 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3847980/
52. Bafiertam™ (monomethyl fumarate) | MSAA - Multiple Sclerosis Association of America, accessed August 21, 2025, https://mymsaa.org/publications/msresearch-update-2020/bafiertam/
53. Very low monomethyl fumarate exposure via human milk: a case report—a contribution from the ConcePTION project - Frontiers, accessed August 21, 2025, https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2024.1393752/full
54. Bafiertam (Monomethyl Fumarate Delayed-release Capsules): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed August 21, 2025, https://www.rxlist.com/bafiertam-drug.htm
55. BAFIERTAM® Patient Prescribing Information for HCPs, accessed August 21, 2025, https://www.bafiertamhcp.com/prescribing-information
56. Tecfidera (dimethyl fumarate) - MS Trust, accessed August 21, 2025, https://mstrust.org.uk/a-z/tecfidera-dimethyl-fumarate
57. Dimethyl fumarate in the management of multiple sclerosis: appropriate | TCRM, accessed August 21, 2025, https://www.dovepress.com/dimethyl-fumarate-in-the-management-of-multiple-sclerosis-appropriate--peer-reviewed-fulltext-article-TCRM
58. Dimethyl Fumarate Shows Efficacy in Phase III Clinical Studies, accessed August 21, 2025, https://www.msdiscovery.org/news/new_findings/3223-dimethyl-fumarate-shows-efficacy-phase-iii-clinical-studies
59. BAFIERTAM® Treatment Efficacy and Clinical Trials, accessed August 21, 2025, https://www.bafiertamhcp.com/treatment-efficacy
60. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis - PubMed, accessed August 21, 2025, https://pubmed.ncbi.nlm.nih.gov/22992072/
61. Positive Results from Phase 3 CONFIRM Clinical Trial Show Efficacy and Safety of Oral BG-12 in Multiple Sclerosis - Biogen | Investor Relations, accessed August 21, 2025, https://investors.biogen.com/news-releases/news-release-details/positive-results-phase-3-confirm-clinical-trial-show-efficacy
62. Tecfidera (Dimethyl Fumarate), Treatment for Relapsing-Remitting Multiple Sclerosis (RRMS) - Clinical Trials Arena, accessed August 21, 2025, https://www.clinicaltrialsarena.com/projects/ms-treatment/
63. Clinical Efficacy of BG-12 (Dimethyl Fumarate) in Relapsing ..., accessed August 21, 2025, https://www.neurology.org/doi/10.1212/WNL.80.7_supplement.P07.097
64. New Data from ENDORSE Show Positive Results Continued over Five Years with TECFIDERA® (Dimethyl Fumarate) in a Wide Range of Multiple Sclerosis Patients, accessed August 21, 2025, https://investors.biogen.com/news-releases/news-release-details/new-data-endorse-show-positive-results-continued-over-five-years
65. Safety and efficacy of delayed-release dimethyl fumarate in patients ..., accessed August 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7222239/
66. Patient BAFIERTAM® (monomethyl fumarate) Brochure, accessed August 21, 2025, https://www.bafiertam.com/pdf/patient-consideration-kit.pdf
67. Monomethyl Fumarate (Professional Patient Advice) - Drugs.com, accessed August 21, 2025, https://www.drugs.com/ppa/monomethyl-fumarate.html
68. What is Tecfidera® (dimethyl fumarate)?, accessed August 21, 2025, https://www.tecfidera.com/en_us/home/about.html
69. BAFIERTAM® Side Effects and Safety Profile in MS Patients, accessed August 21, 2025, https://www.bafiertamhcp.com/safety-profile
70. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BAFIERTAM safely and eff - accessdata.fda.gov, accessed August 21, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210296s007lbl.pdf
71. BAFIERTAM® Direct Delivery Fumarate For MS Patients, accessed August 21, 2025, https://www.bafiertamhcp.com/monomethyl-fumarate
72. Starting or Switching to BAFIERTAM®, accessed August 21, 2025, https://www.bafiertam.com/starting-bafiertam
73. Frequently Asked Questions About BAFIERTAM®, accessed August 21, 2025, https://www.bafiertam.com/faqs
74. Monomethyl Fumarate: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed August 21, 2025, https://www.rxlist.com/monomethyl_fumarate/generic-drug.htm
75. Monomethyl Fumarate Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed August 21, 2025, https://www.drugs.com/dosage/monomethyl-fumarate.html
76. Bafiertam Interactions Checker - Drugs.com, accessed August 21, 2025, https://www.drugs.com/drug-interactions/monomethyl-fumarate,bafiertam.html
77. Monomethyl fumarate Interactions - Drugs.com, accessed August 21, 2025, https://www.drugs.com/drug-interactions/monomethyl-fumarate.html
78. Safety Monitoring for Multiple Sclerosis Patients on Disease Modifying Therapies, accessed August 21, 2025, https://my.clevelandclinic.org/departments/neurological/depts/multiple-sclerosis/ms-approaches/safety-monitoring-multiple-sclerosis-patients-disease-modifying-therapies
79. Bafiertam: Package Insert / Prescribing Information - Drugs.com, accessed August 21, 2025, https://www.drugs.com/pro/bafiertam.html
80. Bafiertam Dosage Guide - Drugs.com, accessed August 21, 2025, https://www.drugs.com/dosage/bafiertam.html
81. BAFIERTAM Patient Information, accessed August 21, 2025, https://www.bafiertam.com/pdf/bafiertam-patient-information.pdf
82. 210296Orig1s000 - accessdata.fda.gov, accessed August 21, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210296Orig1s000SumR.pdf
83. FDA Approves Bafiertam Fumarate Bioequivalent for Relapsing Multiple Sclerosis, accessed August 21, 2025, https://www.neurologylive.com/view/fda-approves-bafiertam-fumarate-bioequivalent-for-relapsing-multiple-sclerosis
84. Bafiertam (monomethyl fumarate) FDA Approval History - Drugs.com, accessed August 21, 2025, https://www.drugs.com/history/bafiertam.html
85. Generic Bafiertam Availability - Drugs.com, accessed August 21, 2025, https://www.drugs.com/availability/generic-bafiertam.html
86. mymsaa.org, accessed August 21, 2025, https://mymsaa.org/news/bafiertam-oral-capsules-approved-by-the-fda-for-relapsing-forms-of-ms/
87. In which countries is Monomethyl fumarate approved? - Patsnap Synapse, accessed August 21, 2025, https://synapse.patsnap.com/article/in-which-countries-is-monomethyl-fumarate-approved
88. Vumerity | European Medicines Agency (EMA), accessed August 21, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/vumerity
89. www.ema.europa.eu, accessed August 21, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/tecfidera#:~:text=Tecfidera%20received%20a%20marketing%20authorisation,EU%20on%2030%20January%202014.
90. Tecfidera | European Medicines Agency (EMA), accessed August 21, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/tecfidera
91. Economic impact of new active substance status on EU payers' budgets: example of dimethyl fumarate (Tecfidera®) for multiple sclerosis - PMC - PubMed Central, accessed August 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4865780/
92. TECFIDERA® (Dimethyl Fumarate) Approved in the European Union as a First-Line Oral Treatment for Multiple Sclerosis - Biogen | Investor Relations, accessed August 21, 2025, https://investors.biogen.com/news-releases/news-release-details/tecfiderar-dimethyl-fumarate-approved-european-union-first-line
93. Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Multiple Sclerosis, Date of authorisation: 30/01/2014, Revision: 28, Status, accessed August 21, 2025, https://efim.org/node/139242
94. Dimethyl fumarate Accord | European Medicines Agency (EMA), accessed August 21, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/dimethyl-fumarate-accord
95. European Commission Approves Biogen's Vumerity as Oral RRMS Therapy, accessed August 21, 2025, https://www.ajmc.com/view/european-commission-approves-biogen-s-vumerity-as-oral-rrms-therapy
96. The European Commission Grants Marketing Authorization for ..., accessed August 21, 2025, https://investors.biogen.com/news-releases/news-release-details/european-commission-grants-marketing-authorization-vumerityr
97. When will the patents on VUMERITY expire, and when will VUMERITY go generic? - DrugPatentWatch, accessed August 21, 2025, https://www.drugpatentwatch.com/p/tradename/VUMERITY
98. Dimethyl fumarate Completed Phase 1 Trials for Relapsing Remitting Multiple Sclerosis (RRMS) Treatment | DrugBank Online, accessed August 21, 2025, https://go.drugbank.com/drugs/DB08908/clinical_trials?conditions=DBCOND0036413&phase=1&purpose=treatment&status=completed
99. Dimethyl fumarate Completed Phase 1 Trials for Multiple Sclerosis Treatment - DrugBank, accessed August 21, 2025, https://go.drugbank.com/drugs/DB08908/clinical_trials?conditions=DBCOND0027885&phase=1&purpose=treatment&status=completed
100. Monomethyl fumarate Completed Phase 1 Trials for Multiple Sclerosis Treatment | DrugBank Online, accessed August 21, 2025, https://go.drugbank.com/drugs/DB14219/clinical_trials?conditions=DBCOND0027885&phase=1&purpose=treatment&status=completed
101. Monomethyl fumarate Terminated Phase Trials for Relapsing Remitting Multiple Sclerosis (RRMS) | DrugBank Online, accessed August 21, 2025, https://go.drugbank.com/drugs/DB14219/clinical_trials?conditions=DBCOND0036413&phase=&status=terminated